{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Placebo+Group&page=9",
    "query": {
      "intervention": "Part 2, Placebo Group",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 280,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Placebo+Group&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Placebo+Group&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T11:49:18.343Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03345836",
      "title": "A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Matching Placebo for Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 624,
      "start_date": "2017-11-29",
      "completion_date": "2021-08-11",
      "has_results": true,
      "last_update_posted_date": "2022-08-15",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 119,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345836"
    },
    {
      "nct_id": "NCT04377945",
      "title": "Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Part 1, JM-010 component Group A",
          "type": "DRUG"
        },
        {
          "name": "Part 1, JM-010 component Group B",
          "type": "DRUG"
        },
        {
          "name": "Part 1, JM-010 component Group C",
          "type": "DRUG"
        },
        {
          "name": "Part 1, Placebo Group",
          "type": "DRUG"
        },
        {
          "name": "Part 2, JM-010 combination Group A",
          "type": "DRUG"
        },
        {
          "name": "Part 2, JM-010 combination Group B",
          "type": "DRUG"
        },
        {
          "name": "Part 2, JM-010 component Group C",
          "type": "DRUG"
        },
        {
          "name": "Part 2, Placebo Group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bukwang Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 41,
      "start_date": "2021-04-28",
      "completion_date": "2024-02-14",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Detroit, Michigan",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04377945"
    },
    {
      "nct_id": "NCT01501383",
      "title": "A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "VX-765 Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "VX-765 Part B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 55,
      "start_date": "2011-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-09-30",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 22,
      "location_summary": "Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01501383"
    },
    {
      "nct_id": "NCT04341441",
      "title": "Will Hydroxychloroquine Impede or Prevent COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "Coronavirus",
        "Coronavirus Infections",
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine - Daily Dosing",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine - Weekly Dosing",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "OTHER"
        },
        {
          "name": "Monitoring Visit - Baseline",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Monitoring Visit - Week 4",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Monitoring Visit - Week 8",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Weekly Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 624,
      "start_date": "2020-04-07",
      "completion_date": "2020-12-15",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04341441"
    },
    {
      "nct_id": "NCT02460874",
      "title": "Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cerebral Edema",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Glyburide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-08-16",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02460874"
    },
    {
      "nct_id": "NCT04444050",
      "title": "Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "BMS-986331",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Matching BMS-986331",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2020-06-23",
      "completion_date": "2021-05-19",
      "has_results": false,
      "last_update_posted_date": "2022-10-20",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Lenexa, Kansas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04444050"
    },
    {
      "nct_id": "NCT02103426",
      "title": "An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dialysis",
        "Healthy Subjects",
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "ASP0113",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-12-30",
      "completion_date": "2016-05-10",
      "has_results": false,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Orlando, Florida • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02103426"
    },
    {
      "nct_id": "NCT05972993",
      "title": "A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "mRNA-CR-04 vaccine 10μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-CR-04 vaccine 30μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-CR-04 vaccine 100μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "mRNA-CR-04 vaccine 3μg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 114,
      "start_date": "2023-08-07",
      "completion_date": "2024-10-14",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05972993"
    },
    {
      "nct_id": "NCT01683071",
      "title": "Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "EXPAREL 67 mg",
          "type": "DRUG"
        },
        {
          "name": "EXPAREL 133 mg",
          "type": "DRUG"
        },
        {
          "name": "EXPAREL 266 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 297,
      "start_date": "2012-09",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2020-12-09",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01683071"
    },
    {
      "nct_id": "NCT02039089",
      "title": "A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "E2006 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 10 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "20 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-01",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2015-11-03",
      "last_synced_at": "2026-10-15T11:49:18.343Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039089"
    }
  ]
}